Laboratorio Reig Jofre (XMAD:RJF) Growth Rank: 7 (As of Aug. 18, 2026) — 75% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XMAD:RJF Laboratorio Reig Jofre SA XMAD:RJF
79 GF Score
Price €2.65
GF Value €2.70
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Laboratorio Reig Jofre Growth Rank?

Laboratorio Reig Jofre XMAD:RJF -0.37% 79 Growth Rank is 7 as of Aug. 18, 2026, which is 75% above its 10-year median of 4.00. GuruFocus rates XMAD:RJF with a GF Score™ of 79/100 and a GF Value™ of €2.70 (Fairly Valued). The stock has 6 warning signs investors should review.

Laboratorio Reig Jofre has the Growth Rank of 7.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Laboratorio Reig Jofre Growth Rank Related Terms

XMAD:RJF vs ZTS, UTHR, VTRS: Growth Rank Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Laboratorio Reig Jofre's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Laboratorio Reig Jofre Growth Rank vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Laboratorio Reig Jofre's Growth Rank distribution charts can be found below:

* The bar in red indicates where Laboratorio Reig Jofre's Growth Rank falls into.


XMAD:RJF
79GF Score
Laboratorio Reig Jofre SA XMAD:RJF
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 7 mean?
Laboratorio Reig Jofre (XMAD:RJF) has a Growth Rank of 7 as of Aug. 18, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Laboratorio Reig Jofre and its competitors. This is 75% above median its historical median of 4.00. Over the past decade, Laboratorio Reig Jofre's Growth Rank has ranged from 1.00 to 9.00.
Is Laboratorio Reig Jofre's Growth Rank too high?
Laboratorio Reig Jofre's current Growth Rank of 7 is 75% above median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 9.00. Overall, Laboratorio Reig Jofre has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Laboratorio Reig Jofre's Growth Rank compare to ZTS and UTHR?
Laboratorio Reig Jofre's Growth Rank of 7 can be compared against companies in the Drug Manufacturers industry. Historically, Laboratorio Reig Jofre's own Growth Rank has ranged from 1.00 to 9.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Drug Manufacturers company?
A good Growth Rank depends on the Drug Manufacturers industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Laboratorio Reig Jofre and its competitors. Laboratorio Reig Jofre's current Growth Rank is 7, which is 75% above median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorio Reig Jofre stock overvalued right now?
Based on GuruFocus' analysis, Laboratorio Reig Jofre (XMAD:RJF) is currently considered Fairly Valued. The stock's GF Value™ is €2.70, compared to a current price of €2.65 — trading 1.9% below its estimated fair value. The current Growth Rank is 7, which is 75% above median its 10-year median of 4.00. Laboratorio Reig Jofre's overall GF Score™ is 79/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Laboratorio Reig Jofre (XMAD:RJF), the current Growth Rank is 7 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Laboratorio Reig Jofre (XMAD:RJF) Overvalued in 2026?

Based on GuruFocus' analysis, Laboratorio Reig Jofre stock appears to be undervalued. The current stock price of €2.65 is trading 1.9% below its estimated GF Value™ of €2.70. GuruFocus considers Laboratorio Reig Jofre to be Fairly Valued.

Key valuation signals for XMAD:RJF:

  • Growth Rank: 7 (75% above median its 10-year median of 4.00)
  • GF Value™: €2.70 vs. price of €2.65 (1.9% below fair value)
  • GF Score™: 79/100 with 6 warning signs

No single metric tells the full story. See the XMAD:RJF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Laboratorio Reig Jofre Business Description

Other Exchanges 0RB1:UKFEQ1:Germany
Address Avenida de les Flors, Sant Joan Despi, Barcelona, ESP, 08970
Laboratorio Reig Jofre SA is a healthcare and pharmaceutical developing company. The company focuses on the development of technological-specialization products (antibiotics and injectable products); therapeutic-specialization products in the areas of dermatology, gynecology and respiratory; and consumer healthcare products. It has a broad portfolio of products that the company divides into three categories: products from specialized technology such as antibiotics, injectable, and freeze-dried products.
79GF Score

Get the complete analysis for XMAD:RJF

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.65
Price
€2.70
GF Value